Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $2.44, $0.14 better than the analyst estimate of $2.30. Revenue for the quarter came in at $328.1 million versus the consensus estimate of $319.74 million.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.